BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9390031)

  • 21. Blockade of T cell costimulation by CTLA4-Ig inhibits lung inflammation in murine hypersensitivity pneumonitis.
    Israël-Assayag E; Fournier M; Cormier Y
    J Immunol; 1999 Dec; 163(12):6794-9. PubMed ID: 10586079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease.
    Kanavaros P; Vlychou M; Stefanaki K; Rontogianni D; Gaulard P; Pantelidaki E; Zois M; Darivianaki K; Georgoulias V; Boulland ML; Gorgoulis V; Kittas C
    Anticancer Res; 1999; 19(2A):1209-16. PubMed ID: 10368677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feline immunodeficiency virus infection is characterized by B7+CTLA4+ T cell apoptosis.
    Tompkins MB; Bull ME; Dow JL; Ball JM; Collisson EW; Winslow BJ; Phadke AP; Vahlenkamp TW; Tompkins WA
    J Infect Dis; 2002 Apr; 185(8):1077-93. PubMed ID: 11930318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells.
    Plumas J; Chaperot L; Jacob MC; Molens JP; Giroux C; Sotto JJ; Bensa JC
    Eur J Immunol; 1995 Dec; 25(12):3332-41. PubMed ID: 8566020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells.
    Manzotti CN; Tipping H; Perry LC; Mead KI; Blair PJ; Zheng Y; Sansom DM
    Eur J Immunol; 2002 Oct; 32(10):2888-96. PubMed ID: 12355442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CTLA-4 (CD152) inhibits the specific lysis mediated by human cytolytic T lymphocytes in a clonally distributed fashion.
    Saverino D; Tenca C; Zarcone D; Merlo A; Megiovanni AM; Valle MT; Manca F; Grossi CE; Ciccone E
    J Immunol; 1999 Jan; 162(2):651-8. PubMed ID: 9916682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A.
    Mukherjee S; Ahmed A; Nandi D
    J Leukoc Biol; 2005 Jul; 78(1):144-57. PubMed ID: 15788440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD30 distribution. Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas.
    Miettinen M
    Arch Pathol Lab Med; 1992 Nov; 116(11):1197-201. PubMed ID: 1332642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence that induction of tolerance in vivo involves active signaling via a B7 ligand-dependent mechanism: CTLA4-Ig protects V beta 8+ T cells from tolerance induction by the superantigen staphylococcal enterotoxin B.
    Lane P; Haller C; McConnell F
    Eur J Immunol; 1996 Apr; 26(4):858-62. PubMed ID: 8625979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Localization in situ of the co-stimulatory molecules B7.1, B7.2, CD40 and their ligands in normal human lymphoid tissue.
    Vyth-Dreese FA; Dellemijn TA; Majoor D; de Jong D
    Eur J Immunol; 1995 Nov; 25(11):3023-9. PubMed ID: 7489738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry.
    Ferenczi K; Burack L; Pope M; Krueger JG; Austin LM
    J Autoimmun; 2000 Feb; 14(1):63-78. PubMed ID: 10648117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NK cell triggering by the human costimulatory molecules CD80 and CD86.
    Wilson JL; Charo J; Martín-Fontecha A; Dellabona P; Casorati G; Chambers BJ; Kiessling R; Bejarano MT; Ljunggren HG
    J Immunol; 1999 Oct; 163(8):4207-12. PubMed ID: 10510357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
    Habib-Agahi M; Phan TT; Searle PF
    Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28.
    Saito K; Sakurai J; Ohata J; Kohsaka T; Hashimoto H; Okumura K; Abe R; Azuma M
    J Immunol; 1998 May; 160(9):4225-31. PubMed ID: 9574523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Costimulatory molecules (CD80 and CD86) on Reed-Sternberg cells are associated with the proliferation of background T cells in Hodgkin's disease.
    Nozawa Y; Wakasa H; Abe M
    Pathol Int; 1998 Jan; 48(1):10-4. PubMed ID: 9589458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel antigen detected by the CBF.78 antibody further distinguishes anaplastic large cell lymphoma from Hodgkin's disease.
    al Saati T; Tkaczuk J; Krissansen G; Print C; Pileri S; Ralfkiaer E; Grogan TM; Meggetto F; Delsol G
    Blood; 1995 Oct; 86(7):2741-6. PubMed ID: 7670113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.
    Salisbury JR; Rapson NT; Codd JD; Rogers MV; Nethersell AB
    J Clin Pathol; 1994 Apr; 47(4):313-7. PubMed ID: 8027367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cells of the phenotype HNK-1 + (CD 57 +) in reactive adenopathies, lymphomas and Hodgkin's disease].
    Merlio JP; Caveriviere P; al Saati T; Coindre JM; de Mascarel A; Delsol G
    Ann Pathol; 1990; 10(3):166-73. PubMed ID: 1696823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity.
    Herrmann A; Lahtz C; Nagao T; Song JY; Chan WC; Lee H; Yue C; Look T; Mülfarth R; Li W; Jenkins K; Williams J; Budde LE; Forman S; Kwak L; Blankenstein T; Yu H
    Cancer Res; 2017 Sep; 77(18):5118-5128. PubMed ID: 28716895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytokines in malignant lymphomas: review and prospective evaluation.
    Hsu SM; Waldron JW; Hsu PL; Hough AJ
    Hum Pathol; 1993 Oct; 24(10):1040-57. PubMed ID: 8406414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.